大成生化科技(00809.HK)：中期股东应占亏损为1.55亿港元

Core Viewpoint - Dachen Biotech (00809.HK) reported a revenue of HKD 1.186 billion for the six months ending June 30, 2025, representing a year-on-year increase of 32% [1] Financial Performance - Revenue reached HKD 1.186 billion, up 32% year-on-year [1] - Gross profit amounted to HKD 161 million, reflecting a significant increase of 144.2% year-on-year [1] - Loss attributable to owners of the company was HKD 155 million, slightly improved from a loss of HKD 158 million in the same period last year [1] - Basic loss per share was HKD 0.017 [1]